Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...
The FDA imposed a partial clinical hold on Biohaven’s opakalim on 4 September 2026, nine days after SK Biopharmaceuticals licensed the Kv7 asset.
Full tozorakimab COPD trial results cut exacerbations across the eosinophil spectrum, including below 150 cells, raising UK biologic access questions.
Novo Nordisk has halted the HERMES and ATHENA IL-6 heart failure trials for futility, leaving ARTEMIS as the last ziltivekimab readout.
Novartis has reported that the pelacarsen trial missed its primary endpoint in 8,323 patients. Lp(a) fell; cardiovascular events did not.
Akeso reports an ivonescimab overall survival benefit over pembrolizumab in HARMONi-2, but no hazard ratio, median or data cutoff was disclosed.
There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...
Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...
For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from 29 May to 2 June in Chicago, drew more than 44,000 oncology professionals and delivered what many clinicians described as some of the most consequential trial data seen at the conference...
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...